Radiotherapy (RT)

RADIATION11 trials

Sponsors

Stanford University, Sun Yat-sen University, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Oslo University Hospital

Conditions

Basal Cell CarcinomaCarcinoma, Squamous Cell of Head and NeckCervical CancerEmbryonal Tumor With Multilayered RosettesEmbryonal Tumor With Multilayered Rosettes, NosHead and Neck Squamous Cell CarcinomaHodgkin LymphomaLocally Advanced Rectal Cancer

Phase 1

REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors

CompletedNCT03317327

Oslo University HospitalHead and Neck Squamous Cell Carcinoma

Start: 2017-09-09End: 2022-11-28Updated: 2025-06-03

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

CompletedNCT03770689

EMD Serono Research & Development Institute, Inc.Locally Advanced Rectal Cancer

Start: 2019-03-20End: 2022-02-21Updated: 2023-03-21

Phase 2

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

CompletedNCT00002774

Stanford UniversitySquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)

Start: 1996-06-30End: 2005-06-30Updated: 2014-06-20

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruitingNCT01154920

M.D. Anderson Cancer CenterHead and Neck Squamous Cell Carcinoma

Start: 2010-07-09End: 2027-12-31Target: 128Updated: 2025-12-17

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

CompletedNCT03122509

Memorial Sloan Kettering Cancer CenterMetastatic Colorectal Cancer

Start: 2017-04-24End: 2021-04-28Updated: 2022-07-06

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Active, not recruitingNCT03407144

Merck Sharp & Dohme LLCHodgkin Lymphoma

Start: 2018-04-09End: 2026-11-06Target: 340Updated: 2026-02-19

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

CompletedNCT03715946

Robert L. Ferris, MD, PhDCarcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma

Start: 2018-11-16End: 2024-03-31Updated: 2025-01-13

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

RecruitingNCT06391034

Robert Bok, MD, PhDProstate Cancer

Start: 2024-09-24End: 2032-10-31Target: 161Updated: 2026-01-07

Embryonal Tumor With Multilayered Rosettes

RecruitingNCT06861244

University of California, San FranciscoEmbryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos

Start: 2025-03-06End: 2032-03-31Target: 70Updated: 2026-03-30

Phase 3

Comparison of Different Subsequent Treatments After Radical Surgery

Sun Yat-sen UniversityCervical Cancer

Start: 2008-02-25End: 2020-12-31Updated: 2019-07-30

Unknown Phase

Skin Cancer and Hyperthermia and Radiotherapy

RecruitingNCT06384053

Kantonsspital Winterthur KSWBasal Cell Carcinoma, Non-melanoma Skin Cancer, Squamous Cell Carcinoma Skin

Start: 2025-01-01End: 2028-07-01Target: 100Updated: 2025-06-15

Related Papers

Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial.

2025-12-22

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood2024-11-052 citations

Circulating Tumor DNA (ctDNA) Assessment in Pediatric Patients with Newly Diagnosed High-Risk Classic Hodgkin Lymphoma (cHL): Exploratory Analysis from the Phase 2 Keynote-667 Study

Blood2024-11-051 citations

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood2024-11-05

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

Clinical Cancer Research2023-12-0528 citations

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Blood2023-11-022 citations

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Blood2023-11-022 citations

Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

Clinical and Translational Science2023-10-313 citations

S215: KEYNOTE-667: OPEN-LABEL, PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY

HemaSphere2023-08-012 citations

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

Journal of Clinical Oncology2023-06-012 citations

PHASE 2 KEYNOTE‐667: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT‐LINE CHEMOTHERAPY

Hematological Oncology2023-06-011 citations

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Journal of Clinical Oncology2023-06-011 citations

P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study

HemaSphere2022-10-01

S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY

HemaSphere2022-06-011 citations

[Chronic radiation-induced rectal injury after adjuvant radiotherapy for pelvic malignant tumors: report based on a phase 3 randomized clinical trial].

PubMed2021-11-252 citations

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.

Journal of Clinical Oncology2021-01-207 citations

Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer

JAMA Oncology2021-01-14117 citations

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

British Journal of Cancer2020-11-24117 citations

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Journal of Clinical Oncology2020-05-206 citations

A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.

Journal of Clinical Oncology2020-05-205 citations

5 more papers not shown